TNFRSF11B and plasma cell myeloma: This released, soluble form of RANKL can diffuse away from the local tumor environment to promote widespread osteoclast activation, thereby contributing to systemic bone loss in myeloma.(14) Interestingly, although myeloma cells do not produce OPG, they can diminish the effect that OPG has on inhibiting osteoclastogenesis.